Why the study?
The role of routine platelet function testing in patients on DAPT after PCI is controversial, and evidence for PFT-guided antiplatelet therapy in STEMI undergoing primary PCI is limited.
Does switching from clopidogrel to ticagrelor reduce MACCEs in STEMI patients with high platelet reactivity undergoing primary PCI?
Does switching from clopidogrel to ticagrelor reduce MACCEs in STEMI patients with high platelet reactivity undergoing primary PCI?
In STEMI patients with high platelet reactivity after primary PCI, switching from clopidogrel to ticagrelor significantly reduces 1-year MACCE and mortality without increasing major bleeding.
No takes yet. Share an insight, caveat, or question.
PFT-guided therapy was associated with fewer ischemic events in STEMI; leaves open whether routine testing improves outcomes pending randomized trials.
You et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: